When most individuals hear the term “dementia,” their minds immediately jump to memory issues and forgetfulness. However, many are unaware that dementia can manifest a wide variety of symptoms impacting speech, behavior, sleep, motor skills, and much more.
In reality, dementia is an umbrella term; it is estimated that over 100 varieties of dementia exist.
Alzheimer’s disease is the most prevalent subtype, accounting for roughly 60% of all cases. Memory loss is one of the most typical indicators associated with this form of dementia.
Nevertheless, approximately 40% of all dementia cases are attributed to other, less common variations. Unfortunately, the presence of a rarer dementia subtype frequently complicates accurate diagnosis and necessitates more involved support.
While most people are likely familiar with certain dementia types, such as Lewy body dementia, Parkinson’s disease dementia, and frontotemporal dementia, awareness of other, rarer forms remains low.
Being able to identify the signs of these less frequent dementia types in their early stages can be crucial for ensuring loved ones receive the necessary assistance.
Posterior Cortical Atrophy
Posterior Cortical Atrophy (PCA) primarily affects visual and spatial abilities. Memory tends to be less impacted in the initial phases compared to Alzheimer’s disease.
Individuals diagnosed with PCA may struggle with visual hallucinations and spatial awareness. This can present itself, for instance, when reading or judging distances on stairs—for example, having difficulty discerning where the next step is located. Symptoms usually emerge between the ages of 55 and 65.
Due to its rarity, a great deal about Posterior Cortical Atrophy (PCA) remains unknown. Researchers are still working to determine whether PCA constitutes a distinct dementia subtype or an atypical presentation of Alzheimer’s disease.
This ambiguity arises because the brain changes observed in PCA sufferers closely resemble those found in Alzheimer’s patients, despite the symptomatic differences. Furthermore, it is theorized that 5% to 15% of people with Alzheimer’s disease actually have PCA.
Creutzfeldt-Jakob Disease
Creutzfeldt-Jakob Disease (CJD) is an extremely rare type of dementia, affecting roughly one in a million people globally.
CJD is categorized as a prion disease. These conditions involve prion proteins which, for unknown reasons, spontaneously adopt an incorrect three-dimensional structure.
The function of healthy prions isn’t fully understood, but they appear to play a role in protecting nerve and brain cells, as well as regulating the body’s circadian rhythm (the natural 24-hour cycle that governs everything from sleep and digestion to immunity).
The misfolding of prion proteins in CJD leads to a dementia that progresses very rapidly and severely, much faster than Alzheimer’s disease or Lewy body dementia, for example.
Besides the marked speed of disease progression, those with CJD exhibit challenges with both memory and movement, including sudden, jerky motions.
Risk factors for this dementia subtype include advanced age and a genetic predisposition (seen in 10-15% of cases). In very rare instances, it can also develop through transmission—such as consuming beef from cattle infected with BSE (Bovine Spongiform Encephalopathy).
FTD-MND represents a form of frontotemporal dementia that coincides with Motor Neuron Disease.
Frontotemporal dementia is a subtype of illness that causes a gradual loss of brain tissue in the frontal and temporal lobes of the brain.
Motor Neuron Disease, conversely, is a rapidly progressing neurological condition that can eventually lead to difficulties with breathing, movement, and paralysis. While it affects the brain and nerves, it is not categorized as a form of dementia on its own.
About 10-15% of individuals with frontotemporal dementia also develop Motor Neuron Disease. This concurrence is seemingly linked to a mutation in the C9orf72 gene. Because of this genetic link, frontotemporal dementia with Motor Neuron Disease can be inherited.
People experiencing both frontotemporal dementia and MND present with numerous muscle-related issues, including muscle wasting, stiffness, and swallowing difficulties. These particular symptoms are often not what people typically associate with dementia and memory problems.
It remains unclear whether the frontotemporal dementia develops first, followed by ALS, or vice versa.
Progressive Supranuclear Palsy
Progressive Supranuclear Palsy (PSP) is a rare neurological disorder that causes both dementia and movement impairments.
It is estimated that around 4,000 people in the UK are affected by this condition. PSP is difficult to diagnose as it mimics or overlaps with several other illnesses, including Parkinson’s disease.
PSP primarily results in damage to the subcortical areas of the brain, specifically the brainstem and basal ganglia. These regions are integral to vision and motor control.
Consequently, people with PSP struggle with visual processing, leading to frequent falls and mobility complications. Those with PSP may also find it hard to maintain focus and solve complex problems.
As is the case with all dementia subtypes, there is currently no cure. While medications exist that can delay the onset of symptoms, they are only effective in instances of Alzheimer’s disease.
Therefore, we must continue to seek ways to support individuals with other dementia subtypes in the most effective manner possible.
One way to achieve this is through a thorough comprehension of their specific condition and its subtype. Knowing that a person might struggle primarily with walking and movement, rather than memory recall, is vital for arranging the correct care well in advance.
It is equally important to recognize the early indicators. Dementia does not solely target memory. Changes in demeanor, visual disturbances, increased falling, alterations in gait or motion, and challenges with articulation—all these could be early indicators of dementia.
A deeper understanding of the numerous forms of dementia will hopefully pave the way for the creation of more effective treatments for this complex illness.
About the Author
